Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03016301 2018-08-30
1
DESCRIPTION
ANTIBODY-CONTAINING PREPARATION
[Technical Field]
The present invention relates to formulations comprising a bispecific antibody
functionally substituting for blood coagulation factor VIII (FVIII) that binds
to blood coagulation
factor IX (FIX) and/or activated blood coagulation factor IX (FIXa) and blood
coagulation factor
X (FX).
[Background Art]
Bispecific antibodies functionally substituting for FVIII that bind to blood
coagulation
factor IX (FIX) and/or activated blood coagulation factor IX (FIXa) and blood
coagulation factor
X (FX) have been discovered (Non-Patent Literature 1 and 2; Patent Literature
1 to 3). The
bispecific antibody Emicizumab (ACE910) ameliorates the decrease in
coagulation reaction due
to FVIII deficiency and dysfunction by functionally substituting for FVIII;
therefore, clinical
trials are being conducted on hemophilia A patients.
Many solution formulations of antibodies have been developed, and solution
formulations of high-concentrated antibodies reported so far are formulations
using histidine and
.. arginine (Patent Literature 4) and formulations using a histidine/aspartate
buffer (Patent
Literature 5). Meanwhile, a stable liquid pharmaceutical antibody formulation
comprising
amyloid 13 (A13) that uses histidine/histidine-HC1 as the buffer (Patent
Literature 6) has been
reported.
However, stable solution formulations in which aggregate formation and/or
components
.. with charge heterogeneity are suppressed have not been reported for
solution formulations
comprising the aforementioned bispecific antibodies.
[Citation List]
[Patent Literature]
[Patent Literature 1] W02005/035756
[Patent Literature 2] W02006/109592
[Patent Literature 3] W02012/067176
[Patent Literature 4] W02002/030463
[Patent Literature 5] W02011/090088
[Patent Literature 6] W02013/131866
[Non-Patent Literature]
CA 03016301 2018-08-30
2
[Non-Patent Literature 1] Nat Med. 2012; 18(10):1570-74
[Non-Patent Literature 2] PLoS One. 2013; 8(2):e57479
[Summary of the Invention]
[Problems to be Solved]
An objective of the present invention is to provide stable solution
formulations
comprising Emicizumab (ACE910) which is a bispecific antibody functionally
substituting for
FVIII that binds to FIX and/or FIXa and FX.
[Means for Solving the Problems]
As a result of dedicated research to accomplish the above-mentioned objective,
the
present inventors discovered that a solution formulation of pH 4.5 to 6.5 that
comprises the
aforementioned bispecific antibody at 20 to 180 mg/mL, 10 mM to 40 mM
histidine/aspartate
buffer, Poloxamer 188 at 0.2 to 1 mg/mL, and 100 mM to 300 mM arginine, can be
a stable
antibody-containing solution formulation in which aggregate formation and/or
components with
charge heterogeneity are suppressed, and thereby completed the present
invention.
Specifically, the present invention provides the following:
[1] An antibody solution formulation of pH 4.5 to 6.5, which comprises:
a bispecific antibody at 20 to 180 mg/mL, wherein a first polypeptide and a
third
polypeptide form a pair, and a second polypeptide and a fourth polypeptide
form a pair, wherein
the first polypeptide comprises an H chain comprising the amino acid sequences
of H-chain
CDRs 1, 2, and 3 of SEQ ID NOs: 1, 2, and 3 (H-chain CDRs of Q499),
respectively; the second
polypeptide comprises an H chain comprising the amino acid sequences of H-
chain CDRs 1, 2,
and 3 of SEQ ID NOs: 4, 5, and 6 (H-chain CDRs of J327), respectively; and the
third
polypeptide and the fourth polypeptide comprise a common L chain comprising
the amino acid
sequences of L-chain CDRs 1, 2, and 3 of SEQ ID NOs: 7, 8, and 9 (L-chain CDRs
of L404),
respectively;
10 mM to 40 mM histidine/aspartate buffer;
0.2 to 1 mg/mL Poloxamer 188; and
100 mM to 300 mM arginine.
[2] The antibody solution formulation of [1], wherein in the bispecific
antibody, the first
polypeptide and the third polypeptide form a pair, and the second polypeptide
and the fourth
polypeptide form a pair, wherein the first polypeptide comprises an H chain
comprising the
amino acid sequence of SEQ ID NO: 10; the second polypeptide comprises an H
chain
comprising the amino acid sequence of SEQ ID NO: 11, and the third polypeptide
and the fourth
polypeptide comprise a common L chain of SEQ ID NO: 12.
[3] The antibody solution formulation of [1] or [2], wherein the concentration
of Poloxamer 188
CA 03016301 2018-08-30
3
is 0.5 mg/mL.
[4] The antibody solution formulation of any one of [1] to [3], wherein said
pH is 6Ø
[5] The antibody solution formulation of any one of [1] to [4], wherein the
concentration of
histidine/aspartate buffer is 20 mM.
[6] The antibody solution formulation of any one of [1] to [5], wherein the
concentration of
arginine is 150 mM.
[7] The antibody solution formulation of any one of [1] to [6], which does not
substantially
contain a chloride ion or an acetate ion.
[8] An antibody solution formulation of pH 6, which comprises:
a bispecific antibody at 20 to 180 mg/mL, wherein a first polypeptide and a
third
polypeptide form a pair, and a second polypeptide and a fourth polypeptide
form a pair, wherein
the first polypeptide comprises an H chain comprising the amino acid sequence
of SEQ ID NO:
10; the second polypeptide comprises an H chain comprising the amino acid
sequence of SEQ ID
NO: 11; and the third polypeptide and the fourth polypeptide comprise a common
L chain of
SEQ ID NO: 12;
mM L-histidine/aspartate buffer;
0.5 mg/mL Poloxamer 188; and
150 mM L-arginine.
[9] The antibody solution formulation of any one of [1] to [8], for use in
subcutaneous
20 administration.
[10] The antibody solution formulation of any one of [1] to [9], for use in
the treatment of
hemophilia A.
[11] A method for stabilizing an antibody in an antibody-containing solution
formulation, which
comprises adding a histidine/aspartate buffer, Poloxamer 188, and arginine to
the solution,
whereby the concentration of the histidine/aspartate buffer is 10 mM to 40 mM,
the
concentration of Poloxamer 188 is 0.2 to 1 mg/mL, and the concentration of
arginine is 100 mM
to 300 mM.
[12] A method for suppressing the association (aggregate formation) of an
antibody in an
antibody-containing solution formulation, which comprises adding a
histidine/aspartate buffer,
Poloxamer 188, and arginine to the solution, whereby the concentration of the
histidine/aspartate
buffer is 10 mM to 40 mM, the concentration of Poloxamer 188 is 0.2 to 1
mg/mL, and the
concentration of arginine is 100 mM to 300 mM.
[13] A method for suppressing a component with charge heterogeneity in an
antibody-containing
formulation, which comprises adding a histidine/aspartate buffer to the
solution, wherein the
concentration of histidine/aspartate buffer is 10 mM to 40 mM.
CA 03016301 2018-08-30
4
[Effect of the Invention]
The present invention provides antibody-containing formulations which show
excellent
stability. Furthermore, providing antibody-containing formulations in which
aggregate
formation and/or components with charge heterogeneity are suppressed in its
solution state has
been also enabled by the present invention.
[Brief Description of the Drawings]
Fig. 1 shows photographs indicating insoluble foreign substances present after
the
shaking tests of EXAMPLE 8 (a: 0 mg/mL Poloxamer188; b: 0.5 mg/mL
Poloxamer188).
Fig. 2 shows graphs indicating the number of insoluble microparticles
(microparticles /
mL) present after the shaking tests and freeze-thawing of EXAMPLE 8.
[Means for Carrying Out the Invention]
The present invention will be described in detail below.
The present invention provides a solution formulation of pH 4.5 to 7.5 that
comprises:
Emicizumab (ACE910) at 20 to 180 mg/mL which is a bispecific antibody
functionally
substituting for FVIII that binds to FIX and/or FIXa and FX; 10 mM to 40 mM
histidine/aspartate buffer; Poloxamer 188 at 0.2 to 1 mg/mL; and 100 mM to 300
mM arginine.
Emicizumab (ACE910), which is the aforementioned bispecific antibody, is
described
below.
A bispecific antibody (Q499-z121/J327-z119/L404-k) where a first polypeptide
and a
third polypeptide form a pair, and a second polypeptide and a fourth
polypeptide form a pair;
where the first polypeptide comprises an H chain comprising the amino acid
sequences of
H-chain CDRs 1, 2, and 3 of SEQ ID NOs: 1, 2, and 3 (H-chain CDRs of Q499),
respectively;
the second polypeptide comprises an H chain comprising the amino acid
sequences of H-chain
CDRs 1, 2, and 3 of SEQ ID NOs: 4, 5, and 6 (H-chain CDRs of J327),
respectively; and the
third polypeptide and the fourth polypeptide comprise a common L chain
comprising the amino
acid sequences of L-chain CDRs 1, 2, and 3 of SEQ ID NOs: 7, 8, and 9 (L-chain
CDRs of
L404), respectively.
More specifically, the aforementioned bispecific antibody is a bispecific
antibody where
a first polypeptide and a third polypeptide form a pair, and a second
polypeptide and a fourth
polypeptide form a pair; where the first polypeptide comprises an H chain
comprising the amino
acid sequence of H-chain variable region of SEQ ID NO: 13, the second
polypeptide comprises
an H chain comprising the amino acid sequence of H-chain variable region of
SEQ ID NO: 14,
and the third polypeptide and the fourth polypeptide comprise a common L chain
comprising the
amino acid sequence of L-chain variable region of SEQ ID NO: 15.
CA 03016301 2018-08-30
More specifically, the aforementioned bispecific antibody is a bispecific
antibody
(Q499-z121/J327-z119/L404-k) where a first polypeptide and a third polypeptide
form a pair,
and a second polypeptide and a fourth polypeptide form a pair; where the first
polypeptide
comprises an H chain comprising the amino acid sequence of SEQ ID NO: 10, the
second
5 polypeptide comprises an H chain comprising the amino acid sequence of
SEQ ID NO: 11, and
the third polypeptide and the fourth polypeptide comprise a common L chain of
SEQ ID NO: 12.
Such antibodies can be obtained by the methods described in W02005/035756,
W02006/109592,
W02012/067176, and such.
The antibody concentration in a formulation of the present invention is not
particularly
limited, but is preferably 20 mg/mL to 180 mg/mL. Examples include 20 mg/mL,
30 mg/mL,
40 mg/mL, 120 mg/mL, 150 mg/mL, and 180 mg/mL. The upper limit of the antibody
concentration of a formulation of the present invention is not particularly
limited, but is
ordinarily 250 mg/mL.
Antibodies used in the present invention are not particularly limited so long
as they bind
to a desired antigen, and they may be polyclonal or monoclonal antibodies.
Monoclonal
antibodies are preferred in that homogeneous antibodies can be stably
produced.
Amino acids contained in the amino acid sequences of the present invention may
be
post-translationally modified (for example, the modification of an N-terminal
glutamine into a
pyroglutamic acid by pyroglutamylation is well-known to those skilled in the
art). Naturally,
such post-translationally modified amino acids are included in the antibodies
used in the present
invention.
In the present invention, the phrase "functionally substituting for FVIII"
means
recognizing FIX or FIXa, and FX, and promoting FX activation by FIXa
(promoting FXa
production by FIXa). FXa production-promoting activity can be evaluated using,
for example,
a measurement system comprising FX1a, FX, synthetic substrate S-2222
(synthetic substrate of
FXa), and phospholipids. Such a measurement system shows a correlation with
the disease
severity and clinical symptoms in hemophilia A cases (Rosen S, Andersson M,
BlombaTck M et
al. Clinical applications of a chromogenic substrate method for determination
of FVIII activity.
Thromb Haemost 1985; 54: 811-23).
In the present invention, the term "common L chain" refers to an L chain that
can form
pairs with each of two or more different H chains, and show binding ability to
each antigen.
Herein, the term "different H chains" preferably refers to H chains of
antibodies against different
antigens, but is not limited thereto; it refers to H chains whose amino acid
sequences are
different from each other. Common L chains can be obtained, for example,
according to the
method described in WO 2006/109592.
In the present invention, the term "stable antibody-containing formulation"
refers to a
CA 03016301 2018-08-30
6
formulation in which aggregates and/or components with charge heterogeneity
from proteins
such as antibodies are difficult to be generated, i.e., the formulations in
which deterioration
reactions, including generation of insoluble aggregates, soluble aggregates,
components with
charge heterogeneity, are difficult to occur in the solution.
"Components with charge heterogeneity" refer to components having protein
surface
charges that are different from those of the major component due to
deamidation, oxidation,
hydrolysis, and such.
In the present invention, "polypeptide" generally refers to peptides and
proteins having
a length of approximately ten amino acids or longer. Ordinarily, they are
biologically derived
polypeptides, but are not particularly limited thereto, and may be, for
example, polypeptides
comprising an artificially designed sequence. Furthermore, they may be any
naturally-occurring polypeptides, synthetic polypeptides, recombinant
polypeptides, or such.
Additionally, fragments of the above-mentioned polypeptides are also included
in the
polypeptides of the present invention.
The term "antibody" is used in the broadest sense, and includes monoclonal
antibodies,
polyclonal antibodies, dimers, multimers, multispecific antibodies (such as
bispecific antibodies),
antibody derivatives, and modified antibodies (Miller K et al. J Immunol.
2003, 170(9),
4854-61) so long as they show a desired biological activity. The antibodies
may be mouse
antibodies, human antibodies, humanized antibodies, chimeric antibodies, or
those derived from
another species, or artificially synthesized antibodies. The antibodies
disclosed herein can be of
any type (for example, IgG, IgE, IgM, IgD, and IgA), class (for example, IgGI,
IgG2, IgG3,
IgG4, IgAl and IgA2) or subclass of immunoglobulin molecules. The
immunoglobulins can be
derived from any species (for example, human, mouse, or rabbit). The terms
"antibody",
"immune globulin" and "immunoglobulin" are used interchangeably in a broad
sense.
"Bispecific antibody" refers to an antibody having two variable regions that
each
recognize different epitopes, where the variable regions are present in the
same antibody
molecule. Bispecific antibodies may be antibodies that recognize two or more
different
antigens, or antibodies that recognize two or more different epitopes on the
same antigen.
Bispecific antibodies may include not only whole antibodies but antibody
derivatives.
Recombinant antibodies produced by using genetic engineering techniques can be
used
as the antibodies. A recombinant antibody can be obtained by cloning a DNA
encoding the
antibody from hybridomas or antibody-producing cells such as sensitized
lymphocytes that
produce antibodies; inserting this into a vector; and then introducing it into
hosts (host cells) to
produce the antibody.
Bispecific antibodies are not limited to those of the IgG type; for example,
IgG-type
bispecific antibodies can be secreted from a hybrid hybridoma (quadroma)
produced by fusing
CA 03016301 2018-08-30
7
two types of hybridomas that produce IgG antibodies (Milstein C. et al.,
Nature 1983, 305:
537-540). They can also be secreted by introducing into cells the L-chain and
H-chain genes
constituting the two kinds of IgGs of interest, i.e., a total of four kinds of
genes, to co-express the
genes.
Antibodies of the present invention can be produced by methods known to those
skilled
in the art. Specifically, a DNA encoding the antibody of interest is inserted
into an expression
vector. The insertion into the expression vector is carried out such that the
expression will take
place under the control of expression regulatory regions such as an enhancer
and a promoter.
Next, host cells are transformed using this expression vector to express the
antibody.
Appropriate combinations of a host and an expression vector can be used in
this case.
The antibodies of the present invention thus obtained can be isolated from the
inside of
host cells or the outside of the cells (medium, etc.), and purified to be
substantially pure,
homogeneous antibodies. The antibodies can be separated and purified by
methods ordinarily
used for separating and purifying antibodies, and the methods are not limited
in any way. For
example, the antibodies can be separated and purified by appropriately
selecting and combining
column chromatography, filtration, ultrafiltration, salting-out, solvent
precipitation, solvent
extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel
electrophoresis,
isoelectrofocusing, dialysis, recrystallization, and such.
In a preferred aspect, the histidine/aspartate buffer in a formulation of the
present
invention is a buffer prepared by titrating a solution such as an aqueous
solution supplemented
with histidine as a free amino acid with a liquid such as an aqueous solution
containing aspartic
acid as a free amino acid. Alternatively, the buffer can be prepared by adding
the amino acids
in the reverse order, or by direct titration with powders.
The present inventors conducted freeze-thawing tests, thermal acceleration
tests, long
term storage tests, and cryopreservation tests to assess the effects of
various additives on the
stability of samples containing the above-mentioned bispecific antibodies
during their storage.
As a result, the present inventors discovered that aggregate formation and/or
components with
charge heterogeneity are suppressed by using a histidine buffer, as compared
to phosphate buffer,
citrate buffer, and acetate buffer.
Furthermore, the present inventors discovered that aggregate formation and/or
components with charge heterogeneity are suppressed by using aspartic acid
which is an acidic
amino acid as a counter ion species for the buffer, i.e., by using
histidine/aspartate buffer as the
buffer.
The concentration (amount) of the histidine/aspartate buffer in formulations
of the
present invention is preferably 10 to 100 mM, and more preferably 10 to 40 mM.
Furthermore,
examples of the concentration (amount) of the histidine/aspartate buffer are
10 mM, 20 mM, and
CA 03016301 2018-08-30
8
40 mM.
Furthermore, compared to sodium chloride which is reported to be a stabilizer
for
antibody-containing formulations, addition of arginine was found to show
higher stabilization
effects (i.e., effects of suppressing aggregate formation and effects of
suppressing components
with charge heterogeneity).
The concentration (amount) of arginine in formulations of the present
invention is
preferably 100 mM to 300 mM. Examples of the arginine concentration (amount)
include 100
mM, 150 mM, 200 mM, and 300 mM.
The solution pH of a formulation of the present invention is preferably 4.5 to
6.5, more
preferably 5.5 to 6.5, and even more preferably 5.5 to 6. Examples of pH
include 5.5 and 6.
Surfactants contained in formulations of the present invention are, for
example
polysorbate 20 (PS20), and Pluronic F-68 (Poloxamer 188: polyethylene (160)
polyoxypropylene
(30) glycol), and Poloxamer 188 is particularly preferred. The amount of
Poloxamer 188 (or
PX188) added to a formulation of the present invention is preferably 0.2 mg/mL
to 1 mg/mL.
Examples of the amount of Poloxamer 188 added to the formulation include 0.2
mg/mL, 0.5
mg/mL, 0.8 mg/mL, and 1 mg/mL.
The histidine used in the present invention may be histidine itself or a
derivative thereof,
and L-histidine is particularly desirable. The arginine used in the present
invention may be
arginine itself, a derivative thereof, or a salt thereof, and L-arginine or a
salt thereof is
particularly desirable. Preferred salts of arginine include aspartate salt and
glutamate salt.
The formulations of the present invention may further contain amino acids.
Preferred
amino acids for use in the present invention are natural amino acids or amino
acid derivatives,
and particularly preferred amino acids are L-methionine and L-proline.
The formulations of the present invention may further contain sugars.
Preferred sugars
.. used in the present invention are sucrose, trehalose, meglumine, and
sorbitol.
The amount of amino acid or sugar added to the formulations of the present
invention is
generally 1 mM to 1000 mM, preferably 5 mM to 500 mM, and more preferably 10
mM to 300
mM.
The formulations of the present invention may further contain inorganic salts.
The
preferred inorganic salts used in the present invention are magnesium salts
and calcium salts.
Furthermore, it is preferred that the formulations of the present invention do
not contain
anions other than aspartic acid as a counter ion for the buffer (buffering
agent) or stabilizer. In
an aspect, examples of such formulations include formulations that do not
substantially contain
chloride ion or acetate ion. "Substantially do not contain chloride ion or
acetate ion" means
that the concentrations of chloride ion and acetate ion are, for example, 5 mM
or less, preferably
2 mM or less, and more preferably 1 mM or less. Highly stable antibody-
containing
CA 03016301 2018-08-30
9
formulations can be produced without increasing the osmotic pressure by using
aspartic acid
which has a large stabilizing effect as a counter ion and not substantially
including chloride ion
or acetate ion with a small stabilization effect.
If needed, the formulations of the present invention may additionally contain
appropriate cryoprotectants, suspending agents, solubilizing agents,
isotonizing agents,
preservatives, adsorption inhibitors, diluents, excipients, pH adjustors,
analgesics,
sulfur-containing reducing agents, antioxidants, and such.
Cryoprotectants include, for example, sugars such as trehalose, sucrose, and
sorbitol.
Solubilizing agents include, for example, polyoxyethylene hardened castor oil,
polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol,
and castor oil
fatty acid ethyl ester.
Isotonizing agents include, for example, sodium chloride, potassium chloride,
and
calcium chloride.
Preservatives include, for example, methyl-p-hydroxybenzoate,
ethyl-p-hydroxybenzoate, sorbic acid, phenol, cresol, and chlorocresol.
Adsorption inhibitors include, for example, human serum albumin, lecithin,
dextran,
ethylene oxide/propylene oxide copolymer, hydroxypropyl cellulose, methyl
cellulose,
polyoxyethylene hardened castor oil, and polyethylene glycol.
Sulfur-containing reducing agents include, for example, those containing
sulfhydryl
groups such as N-acetylcysteine, N-acetylhomocysteine, thioctic acid,
thiodiglycol, thioethanol
amine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, sodium
thiosulfate,
glutathione, and thioalkanoic acids having one to seven carbon atoms.
Antioxidants include, for example, erythorbic acid, dibutylhydroxytoluene,
butylhydroxyanisole, ct-tocopherol, tocopherol acetate, L-ascorbic acid and
salts thereof,
L-ascorbic acid palmitate, L-ascorbic acid stearate, sodium hydrogen sulfite,
sodium sulfite,
triamyl gallate, propyl gallate, and chelating agents such as disodium
ethylenediamine
tetraacetate (EDTA), sodium pyrophosphate, and sodium metaphosphate.
In an embodiment, the formulation of the present invention is the following:
an antibody solution formulation of pH 6, which comprises:
a bispecific antibody at 20 to 180 mg/mL, wherein a first polypeptide and a
third
polypeptide form a pair, and a second polypeptide and a fourth polypeptide
form a pair, wherein
the first polypeptide comprises an H chain comprising the amino acid sequence
of SEQ ID NO:
10, the second polypeptide comprises an H chain comprising the amino acid
sequence of SEQ ID
NO: 11, and the third polypeptide and the fourth polypeptide comprises a
common L chain of
SEQ ID NO: 12;
20 mM L-histidine/aspartate buffer;
CA 03016301 2018-08-30
0.5 mg/mL Poloxamer 188; and
150 mM L-arginine;
Or
an antibody solution formulation of pH 6, which comprises:
5 the bispecific antibody Emicizumab (ACE910) at 20 to 180 mg/mL,
mM L-histidine/aspartate buffer;
0.5 mg/mL Poloxamer 188; and
150 mM L-arginine.
In another embodiment, the formulation of the present invention is the
following:
10 an antibody solution formulation of pH 6, which comprises:
a bispecific antibody at 20 to 180 mg/mL, wherein a first polypeptide and a
third
polypeptide form a pair, and a second polypeptide and a fourth polypeptide
form a pair, wherein
the first polypeptide comprises an H chain comprising the amino acid sequence
of SEQ ID NO:
10, the second polypeptide comprises an H chain comprising the amino acid
sequence of SEQ ID
15 NO: 11, and the third polypeptide and the fourth polypeptide comprise a
common L chain of
SEQ ID NO: 12;
20 mM L-histidine/aspartate buffer;
0.05 mg/mL PS20; and
150 mM L-arginine;
20 or
an antibody solution formulation of pH 6, which comprises:
the bispecific antibody Emicizumab (ACE910) at 20 to 180 mg/mL,
20 mM L-histidine/aspartate buffer;
0.05 mg/mL PS20; and
150 mM L-arginine.
The antibody-containing formulations of the present invention can be
administered to a
patient via any appropriate route, for example, by bolus injection or
continuous infusion for a
certain period, intravenously, intramuscularly, or subcutaneously. Intravenous
administration or
subcutaneous administration is preferred.
The dosage of Emicizumab (ACE910) is, for example, 0.001 to 1000 mg/kg, and
the
interval of administration is at least one day or longer.
More specifically, for example, after administering Emicizumab (ACE910) at an
initial
dose of 1 mg/kg, Emicizumab (ACE910) can be administered at a continuous dose
of 0.3 mg/kg
once a week. Alternatively, for example, after administering Emicizumab
(ACE910) at an
initial dose of 3 mg/kg, Emicizumab (ACE910) can be administered at a
continuous dose of 1
mg/kg once a week. In another example, after administering Emicizumab (ACE910)
at an
CA 03016301 2018-08-30
11
initial dose of 3 mg/kg, Emicizumab (ACE910) can be administered at a
continuous dose of 3
mg/kg once a week.
Antibody-containing formulations of the present invention can be used for
diseases that
develop and/or progress due to the reduction or deficiency in the activity of
FVIII and/or
activated blood coagulation factor VIII (F Villa). For example, they can be
used for hemophilia
A, hemophilia A in which an inhibitor against FVIII /FVIIIa has appeared,
acquired hemophilia
A, von Willebrand's disease, without being particularly limited thereto.
Another embodiment of the present invention is a method for stabilizing an
antibody in
an antibody-containing solution formulation. Preferably, the method for
stabilizing an antibody
in an antibody-containing solution formulation comprises adding a
histidine/aspartate buffer,
Poloxamer 188, and arginine to the solution.
Another embodiment of the present invention is a method for reducing
association
(aggregate formation) of an antibody in an antibody-containing solution
formulation.
Preferably, the method for reducing association (aggregate formation) of an
antibody in an
antibody-containing solution formulation comprises adding a
histidine/aspartate buffer,
Poloxamer 188, and arginine to the solution.
Furthermore, the above-mentioned method for stabilizing an antibody and method
for
reducing association (aggregate formation) of an antibody comprise adding a
histidine/aspartate
buffer, Poloxamer 188, and arginine to the solution, and preferably the
antibody concentration is
20 to 180 mg/mL, histidine/aspartate buffer concentration is 10 mM to 40 mM,
Poloxamer 188
concentration is 0.2 to 1 mg/mL, arginine concentration is 100 mM to 300 mM,
and pH is 4.5 to
6.5; or more preferably the antibody concentration is 20 to 180 mg/mL,
histidine/aspartate buffer
concentration is 20 mM, Poloxamer 188 concentration is 0.5 mg/mL, arginine
concentration is
150 mM, and pH is 6.
Another embodiment of the present invention is a method for decreasing a
component
with charge heterogeneity in an antibody-containing formulation. Preferably,
the method for
decreasing a component with charge heterogeneity in an antibody-containing
formulation
comprises adding a histidine/aspartate buffer to the solution. More
preferably, the method for
decreasing a component with charge heterogeneity in an antibody-containing
formulation
comprises adding a histidine/aspartate buffer to the solution, where the
histidine/aspartate buffer
concentration is 10 mM to 40 mM, or at 20 mM.
In another embodiment of the present invention, the method for decreasing a
component
with charge heterogeneity in an antibody-containing formulation comprises
adding a
histidine/aspartate buffer, Poloxamer 188, and arginine to the solution. More
preferably, the
method for decreasing a component with charge heterogeneity in an antibody-
containing
formulation comprises adding a histidine/aspartate buffer, Poloxamer 188, and
arginine to the
CA 03016301 2018-08-30
12
solution, and preferably the antibody concentration is 20 to 180 mg/mL,
histidine/aspartate
buffer concentration is 10 mM to 40 mM, Poloxamer 188 concentration is 0.2 to
1 mg/mL,
arginine concentration is 100 mM to 300 mM, and pH is 4.5 to 6.5, or more
preferably the
antibody concentration is 20 to 180 mg/mL, histidine/aspartate buffer
concentration is 20 mM,
.. Poloxamer 188 concentration is 0.5 mg/mL, arginine concentration is 150 mM,
and pH is 6.
In the above-mentioned method for stabilizing an antibody, the method for
reducing
association (aggregate formation) of an antibody, and the method for
decreasing a component
with charge heterogeneity, the antibody is preferably a bispecific antibody
and more preferably
Emicizumab (ACE910).
As used herein, aspects referred to by the expression "comprising" include
those
referred to by the expression "essentially consisting of', and those referred
to by the expression
"consisting of'.
Numerical values recited herein may vary within a certain range, for example,
depending on the instruments or equipment, measurement conditions, and
procedure used by
those skilled in the art, and so long as they are within a range that allows
the objective of the
invention to be accomplished, they may encompass a deviation of approximately
10%, for
example.
All patents and references explicitly cited herein are incorporated by
reference into this
specification in its entirety.
The present invention will be further illustrated by the Examples below, but
it is not to
be construed as being limited thereto.
[Examples]
[Example 1]
Aggregate-suppressing effects of histidine during thermally accelerated
storage of the humanized
IgG4 antibody ACE910
(1) Materials
ACE910 is a bispecific humanized IgG4 antibody that recognizes both blood
coagulation factor IX and blood coagulation factor X, which is expected to
prevent bleeding in
hemophilia A by functionally substituting for activated blood coagulation
factor VIII.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 100 mg/mL, NaC1 at 150
mmol/L,
and any one the following buffers: Phosphate buffer at 20 mmol/L; Citrate
buffer at 20 mmol/L;
.. Acetate buffer at 20 mmol/L; and Histidine buffer at 20 mmol/L, were
prepared. Glass vials
were respectively filled with 5 to 15 !IL of the compositions.
CA 03016301 2018-08-30
13
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a thermo-regulated bath at 25 C for eight weeks, and then used as test
samples.
(3) Methods for measuring and calculating the amount of ACE910 aggregates
The amounts of aggregates in the samples were measured by size exclusion
chromatography (SEC) using a G3000SWxL (Tosoh) column with phosphate buffer
(50 mmol/L,
pH7.0) containing sodium chloride at 300 mmol/L for the mobile phase at a flow
rate of 0.5
mL/min.
Of the detected peaks, the peak with the largest area and height was
determined to be
the monomer, and the peaks detected earlier than the monomer were collectively
referred to as
aggregate peaks (high molecular weight species, HMWS).
The peak areas were calculated for all of the peaks, and the peak area ratio
of the peak
of interest was calculated using the following equation:
The peak area ratio of the peak of interest (%) = 100 x (the peak area of the
peak of interest) /
(the peak area of the peak of interest + the total peak area of the other
peaks)
(4) Results
The obtained results are shown in Table 1.
[Table 1]
Increase in aggregates 00 after storage at 25 C
ANN (%)
Formulation =
250C-201 25 C-4W 25 C-8V4
Phosphate 0. 20 0. 27 0. 41
Citrate 0.14 0.21 0.32
Acetate 0.24 0.38 063
H st i d i ne 0.08 0.13 0.22
As is clear from Table 1, when supplemented with histidine at 20 mmol/L, the
sample
showed a high aggregate-suppressing effect after thermal acceleration at 25 C
for eight weeks.
[Example 2]
Aggregate-suppressing effects of the salt concentration and arginine during
thermally accelerated
storage and freeze-thawing of the humanized IgG4 antibody ACE910
CA 03016301 2018-08-30
14
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 100 mg/mL, Histidine at 20
mmol/L, and any one of the following additives: NaC1 at 50 mmol/L; NaC1 at 75
mmol/L; NaCl
at 150 mmol/L; and Arginine at 150 mmol/L, were prepared. Glass vials were
respectively
filled with 5 to 15 tL of the compositions.
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a thermo-regulated bath at 25 C for eight weeks, or were subjected to ten
cycles of
freeze-thawing (FIT) (5 C/-20 C), and then used as test samples.
(3) Methods for measuring and calculating the amount of ACE910 aggregates
The methods were performed as described in Example 1.
(4) Results
The obtained results are shown in Table 2.
[Table 2]
Increase in aggregates 00 after storage at 250 C and after freeze¨thawing
A HM01(%)
Formulation
5F/T 10F/T 25 C-20/ 25 c-4W 25 C-8W
50mM NaC I 1.00 2.07 0.09 0.16 0.26
75mM NaC I 0.62 1.43 0.07 0.13 0.23
150mM Net 0.11 0.28 0.08 0.13 0.22
150mM Arg 0. 03 0. 05 0. 03 O. 06 0. 11
As is clear from Table 2, when supplemented with arginine at 150 mmol/L, the
samples
showed a high aggregate-suppressing effect after the thermal acceleration test
at 25 C for eight
weeks and the freeze-thawing.
[Example 3]
Aggregate-suppressing effects of aspartic acid during freeze-thawing of the
humanized IgG4
antibody ACE910
(1) Materials
CA 03016301 2018-08-30
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 100 mg/mL, Histidine at 20
5 mmol/L, and NaC1 at 150 mmol/L or sodium L-Aspartic acid at 150 mmol/L as
the counter ion,
were prepared. Glass vials were respectively filled with 5 to 15 uL of the
compositions.
Humanized antibody-containing solution formulations thus prepared were
subjected to
ten cycles of freeze-thawing (5 C/-20 C), and then used as test samples.
10 (3) Methods for measuring and calculating the amount of ACE910
aggregates
The methods were performed as described in Example 1.
(4) Results
The obtained results are shown in Table 3.
[Table 3]
Increase in aggregates 0/0 after freeze¨thawing
NW (%)
Formulation
5F/T 10F/1
NaC I 0.11 0.28
Na Aspartic acid 0.05 0.13
As is clear from Table 3, when supplemented with aspartic acid, the samples
showed a
high aggregate-suppressing effect after the freeze-thawing.
[Example 4]
Effects of suppressing aggregates and components with charge heterogeneity by
pH during
thermally accelerated storage of the humanized IgG4 antibody ACE910
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions containing ACE910 at 100 mg/mL, Histidine-Aspartic acid at
20
mmol/L, and Arginine-Aspartic acid at 150 mmoUL, and having pH of 4.5, 5.0,
5.5, 6.0, 6.5, 7.0,
CA 03016301 2018-08-30
16
or 7.5 were prepared. Glass vials were respectively filled with 5 to 15 [iL of
the compositions.
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a thermo-regulated bath at 25 C for eight weeks, and then used as test
samples.
(3) Methods for measuring and calculating the amount of ACE910 aggregates
The methods were performed as described in Example 1.
(4) Methods for measuring and calculating ACE910 components with charge
heterogeneity
The amount of components with charge heterogeneity in a sample was measured by
ion
exchange chromatography (IEC) through a BioPro QA-F column (YMC) using Tris-
HC1 buffer
(20 mmol/L, pH 7.8) as mobile phase A and Tris-HC1 buffer (20 mmol/L, pH7.8)
containing
sodium chloride (500 mmol/L) as mobile phase B, at a flow rate of 0.5 mL/min.
Of the detected peaks, the peak with the largest area and height was
determined to be
the Main peak, and the peaks detected later than the Main peak were
collectively referred to as
the Acidic peak.
The peak area was calculated for all of the peaks, and the peak area ratio of
the peak of
interest was calculated using the following equation:
The peak area ratio of the peak of interest (%) = 100 x (the peak area of the
peak of interest) /
(the peak area of the peak of interest + the total peak area of the other
peaks)
(5) Results
The obtained results are shown in Table 4.
[Table 4]
CA 03016301 2018-08-30
17
Increase in aggregates (%) and increase in Acidic peak-1 (%)
after storage at 25 C
is. HMV a) dAcidic-1 (%)
Formulation
= 25 C-2W 25 C-4W 25 C-8W 25 C-2W 25 C-4W 25 C-8W
pH4. 5 005 0.10 0.24 0.21 2.43 3.41
p115.0 009 0.11 0.20 0.46 0.86 2.57
p115. 5 0, 07 0.08 O. 15 0.36 0. 68 2,
10
p116.0 0.07 0.11 0.17 0.38 0.47 3.23
pH6. 5 0. 09 O. 14 0. 25 0. 24 1.
17 3. 90
pH7. 0 0.13 0.17 0.30 1.25 2.44
5.39
pH7. 5 0.18 0.32 0.79 3.09 5.01 9.49
As is clear from Table 4, the samples at pH 4.5 to 6.5, and in particular at
pH 5.5 and pH
6.0, showed a high effect of suppressing aggregates and components with charge
heterogeneity
after storage at 25 C.
[Example 5]
Effects of suppressing aggregates and components with charge heterogeneity by
the histidine
concentration during thermally accelerated storage of the humanized IgG4
antibody ACE910
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 100 mg/mL, Arginine at 150
mmol/L, and Histidine-aspartic acid at 5 mmol/L, 10 mmol/L, 20 mmol/L, or 40
mmol/L were
prepared. Glass vials were respectively filled with 5 to 15 tL of the
compositions.
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a thermo-regulated bath at 25 C for eight weeks, and then used as test
samples.
(3) Methods for determining and calculating the amount of ACE910 aggregates
The methods were performed as described in Example 1.
(4) Methods for measuring and calculating ACE910 components with charge
heterogeneity
The methods were performed as described in Example 4.
CA 03016301 2018-08-30
18
(5) Results
The obtained results are shown in Table 5.
[Table 5]
Increase in aggregates 00 and increase in Acidic peak-1 (%) after storage at
25 C
Histidine KM (%) AAcidic-1 (%)
concentration 25 C-2W 25 C-41N 25 C-8f1 25 C-2i 25 C-4W 25 C-8Vi
5 mmo I /L 0.04 0.09 0.17 0.87 3.01 9.19
mmo I /I_ 0.02 0.05 0.14 0.39 1.50 7.09
mmo I /L 0.01 0.04 0.12 0,06 1.04 7.11
40 mmo I /L 0.01 0.02 0.07 0.52 1.13 6.74
As is clear from Table 5, the samples containing 10 mmol/L or more of
Histidine-aspartic acid showed a high effect of suppressing aggregates and
components with
10 charge heterogeneity after storage at 25 C.
[Example 6]
Aggregate-suppressing effects of the arginine concentration during freeze-
thawing, thermally
accelerated storage, and cryopreservation of the humanized IgG4 antibody
ACE910
15 (1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 100 mg/mL, Histidine-
aspartic
20 acid at 20 mmol/L, and Arginine at 75 mmol/L, 100 mmol/L, 150 mmol/L,
200 mmol/L, or 300
mmol/L were prepared. Glass vials were respectively filled with 5 to 15 [IL of
the
compositions.
Humanized antibody-containing solution formulations thus prepared were
subjected to
ten cycles of freeze-thawing (5 C/-20 C), or left to stand in a thermo-
regulated bath at 25 C for
eight weeks or at -20 C for six months, and then used as test samples.
(3) Methods for measuring and calculating the amount of ACE910 aggregates
The methods were performed as described in Example 1.
(4) Results
CA 03016301 2018-08-30
19
The obtained results are shown in Table 6.
[Table 6]
Increase in aggregates (%) after freeze-thawing, after storage at 25 C,
and after storage at -20 C
A HMO/ (%)
Arginine
-20 c -
20ct
concentration 5F/T 10F/T 25 C-21N 25 C-4W 25 C-81V
-34 -6M
75 mmol/L 0.10 0.10 0.02 0,06 0.17 0.19
0.53
100 mmol/L 0.04 0.04 0,01 0.04 0.12 0.08
0.02
150 mmol/L 0.01 0.01 -0,01 0.01 0.04 0.00
0.00
200 mmol/L 0.01 0.01 -0.01 0.00 0.02 0.00 -
0.01
300 mmol/L 0.00 0.00 -0.02 -0.02 0.00 0.00 -
0.01
As is clear from Table 6, the samples containing Arginine at 100 mmol/L or
more
showed high aggregate-suppressing effects after freeze-thawing, after storage
at 25 C, and after
storage at -20 C.
[Example 7]
Effects of suppressing insoluble foreign substances and insoluble
microparticles by Poloxamer
188 during storage at 5 C of the humanized IgG4 antibody ACE910
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 80 mg/mL, Histidine-
Aspartic
acid at 20 mmol/L, Arginine at 150 mmol/L, and any one of the following
additives: Poloxamer
188 at 0 mg/mL; Poloxamer 188 at 0.2 mg/mL; Poloxamer 188 at 0.5 mg/mL;
Poloxamer 188 at
1.0 mg/mL; Polysorbate20 at 0.05 mg/mL; and Polysorbate20 at 1.0 mg/mL, were
prepared.
Glass vials were respectively filled with 1.0 mL of the compositions.
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a refrigerator at 5 C for five months, and then used as test samples.
(3) Method for observing insoluble foreign substances
The presence of insoluble foreign substances was assessed by placing the
sample on a
sample platform of a visual examination stand for vials, rotating the sample
platform, and
CA 03016301 2018-08-30
observing the vial.
(4) Method for measuring insoluble microparticles
The number of insoluble microparticles in a solution was determined using a
liquid
5 microparticle counter (Hach Ultra Analytics, Model 9703).
(5) Results
The obtained results are shown in Table 7.
10 [Table 7]
Number of insoluble microparticles (microparticles / mL) and detection rate of
insoluble foreign substances (%)
after storage at 5 C
O. 2mg/mL O. 5mg/mL
1. Omg/mL
PX188
-
Initial 1 1M ! 3M 5M Initial 1M
3M 5M Initial 1M 3M 5M
Number of .1 51./ni 31 ¨ ! 61 188 9 ¨ 18 27
7 ¨ 1 43
insoluble Ili cropart i c les ?.
'
. 10 ti m 5 ¨ , 4 15 5 ¨ 3 2 5 ¨ 3
5
microparticles / lc . -
in solution 25tim 1 ¨ 1 1 1 1 ¨ 0
0 0 ¨ 1 1
Detection rate of insoluble foreign substances
(number of vials containing foreign substances '
i number of examined vials) 0/5 0/5 1 0/5 0/5 0/5 0/5
0/5 0/5 0/5 , 0/5 0/5 0/5
PS20 0. 05 mg/mL 1. 0 ment
Initial 1M 3M 5M Initial 1M 3M
5M
_ , _
,
P
Number of ?. 5 ii m 13 , ¨ 36 89 24 ¨ 238
411
insoluble Oh cropart [cies
2
o
> 10/i m 5 ¨ i 3 10 9 ¨ 49 66
,
microparticles /mu
.
in solution 1 k 251.im 0 ¨ i 0 0 1 ¨ 3 2
I.)
_
.
,
-Detection rate of insoluble foreign substances-
,
.3
(fluter of vials containing foreign substances
'
0/5 0/5 0/5 0/5 0/5 0/5
5/5 5/5 '
i number of examined vials)
T
CA 03016301 2018-08-30
22
As is clear from Table 7, the samples containing PS20 at 0.05 mg/mL and the
samples
containing Poloxamer 188 at 0.2 mg/mL or more showed a high effect of
suppressing the
formation of insoluble microparticles and insoluble foreign substances after
storage at 5 C.
[Example 8]
Effects of suppressing insoluble foreign substances and insoluble
microparticles by Poloxamer
188 during a shaking stress and freeze-thaw storage of the humanized IgG4
antibody ACE910
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing ACE910 at 150 mg/mL, Histidine-
Aspartic
acid at 20 mmol/L, Arginine-Aspartic acid at 150 mmol/L, and any one of the
following
additives: Poloxamer 188 at 0 mg/mL; Poloxamer 188 at 0.2 mg/mL; Poloxamer 188
at 0.5
mg/mL; and Poloxamer 188 at 0.8 mg/mL, were prepared. Glass vials were
respectively filled
with 0.9 mL of the compositions.
Humanized antibody-containing solution formulations thus prepared were
subjected to
shaking for 24 hours at a speed of 200 strokes/min using a shaker at room
temperature, or ten
cycles of freeze-thawing (5 C/-20 C), and then used as test samples.
(3) Method for observing insoluble substances
The method was performed as described in Example 7.
(4) Method for measuring insoluble microparticles
The method was performed as described in Example 7.
(5) Results
The obtained results are shown in Table 8 and Figures 1 and 2.
[Table 8]
CA 03016301 2018-08-30
23
Detection rate (%) for insoluble foreign substances
after shaking and freeze-thaw storage
Detect ion rate for insoluble foreign substances
(number of vials containing foreign substances / number of examined vials)
Poloxamer 188
concentration Initial Shaking for Shaking for Freeze-
thawing
30 minutes 24 hours
0 mg/mL 0% (0/10) 50% (5/10) 100% (10/10) 0% (0/10)
0.2 mg/mL 0% (0/10) 0% (0/10) 0% (0/10) 0% (0/10)
O. 5 mg/mL 0% (0/10) 0% (0/10) 0% (0/10) 0% (0/10)
0.8 mg/mL 0% (0/10) 0% (0/10) 0% (0/10) 0% (0/10)
As is clear from Table 8 and Figures 1 and 2, the samples containing Poloxamer
188 at
0.2 mg/mL or more showed a high effect of suppressing the formation of
insoluble
microparticles and insoluble foreign substances after being subjected to
shaking stress and
freeze-thaw storage.
[Example 9]
Effects of the concentration of humanized IgG4 antibody ACE910 on the
stability during
thermally accelerated storage and freeze-thaw storage
(1) Materials
The antibody described in Example 1 was used.
(2) Test samples
Liquid compositions of pH 6.0 containing Histidine-Aspartic acid at 20 mmol/L,
Arginine-Aspartic acid at 150 mmol/L, Poloxamer 188 at 0.5 mg/mL, and ACE910
at 20 mg/mL,
30 mg/mL, 40 mg/mL, 120 mg/mL, 150 mg/mL, or 180 mg/mL were prepared. Glass
vials
were respectively filled with 0.65 mL of the compositions.
Humanized antibody-containing solution formulations thus prepared were left to
stand
in a thermo-regulated bath at 40 C for eight weeks, or subjected to five or
ten cycles of
freeze-thawing (25 C/-20 C), and then used as test samples.
(3) Methods for measuring and calculating the amount of ACE910 aggregates
The methods were performed as described in Example 1.
CA 03016301 2018-08-30
24
(4) Methods for measuring and calculating ACE910 components with charge
heterogeneity
The amount of components with charge heterogeneity in a sample was measured by
anion exchange chromatography (AIEC) through a TSKgel Q-STAT column (Waters)
using
Tris-HC1 buffer (50 mmol/L, pH 8.0) as mobile phase A and Tris-HC1 buffer (50
mmol/L, pH8.0)
containing sodium chloride (200 mmol/L) as mobile phase B at a flow rate of
0.5 mL/min.
Of the detected peaks, the peak with the largest area and height was
determined to be
the Main peak, and the peaks detected earlier than the Main peak were
collectively referred to as
the Basic peaks and the peaks detected later than the Main peak were
collectively referred to as
the Acidic peaks.
Furthermore, the amount of components with charge heterogeneity was measured
by
cation exchange chromatography (CIEC) through a ProPac WCX-10G column (Thermo
Scientific) using a buffer containing Tris at 9.6 mmol/L, piperazine at 6.0
mmol/L, and imidazole
at 11.0 mmol/L (pH 6.0) as mobile phase A and a buffer containing Tris at 9.6
mmol/L,
piperazine at 6.0 mmol/L, imidazole at 11.0 mmol/L, and NaCl at 100 mmol/L (pH
10.1) as
mobile phase B at a flow rate of 0.5 mL/min.
Of the detected peaks, the peak with the largest area and height was
determined to be
the BiAb peak, the peaks detected earlier than the BiAb peak were collectively
referred to as the
Pre peaks and the peaks detected later than the BiAb peak were collectively
referred to as the
Post peaks.
The peak area was calculated for all of the peaks, and the peak area ratio of
the peak of
interest was calculated using the following equation:
The peak area ratio of the peak of interest (%) = 100 x (the peak area of the
peak of interest) /
(the peak area of the peak of interest + the total peak area of the other
peaks)
(5) Results
The obtained results are shown in Table 9. "SE", "AE", and "CE" respectively
indicate the results from size exclusion chromatography, anion exchange
chromatography, and
cation exchange chromatography.
[Table 9]
CA 03016301 2018-08-30
Amounts of aggregates (%) and ononents with charge heterogeneity after
storage at 40 C and after freeze-thawing
ACE910 conc. (mg/mi..) 20 30 40 120 150 180
Initial 0.10 0.11 0.11 0,13 0.14 0,14
2 weeks 40 C 0. 14 0. 15 0, 16 0. 26 0.28 0.31
SE-HPLC
% HMWS
4 weeks 40 C 0.16 0.17 0.20 0.34 0.38 0.44
_
cycles FIT 0.11 0.11 0.12 0.13 0.14 0.14
10 cycles F/T 0.11 0.11 0.11 0.13 0.13 0.14
Initial 99.90 99.89 99,89 99.87 99.86 99.86
2 weeks 40 C 99. 86 99. 85 99, 84 99. 74 99. 72 99. 69
SE-HPLC
4 weeks 40 C 99.84 99.83 99,80 99.66 99.62 99.56'
% Monomer
5 cycles F/T 99.89, 99.89 99.88 99.87 99.86 99.86
10 cycles Fir 99.89, 99.89 99.89 99.87 99.87' 99.86
Initial 16.1 16,2 16.1 16.3 16.0 16.3
AE-HPLC 2 weeks 40 C 14.3 14.6 14.4 14.5 14.5 14.5
% Basic 4 weeks 40 C 12.7 12.8 12,8 12.8 12.7 12.7
region 5 cycles FiT 16.1 16.2 16.4 16.5 16.5 16.5
10 cycles Fir 15,9 16.0 16.2 16.4 16.5 16.4
Initial 71.7 71.6 71.8 71.5 72.1 71.6
AE-HPLC 2 weeks 40 C 65,0 64,6 64.7 64,5 63.9 64.4
4 weeks 40 C 58.3 57,8 57.8 57.2 57.3 57.5
% Ma i n
5 cycles F/T 72.3 72.2 72.0 71.6 71.6 71.6
10 cycles F/T 72.7 72.4 72.1 71.5 71.6 71.7
Initial 12.1 12.2 12.1 - 12.2 11.9 12.1
AE-HPLC 2 weeks 40 C 20. 7 20. 8 20. 9 20. 9 21. 6 21. 1
% Acdic 4 weeks 40 C 29. 0 29. 4 29. 4 30. 0 30. 0 29. 8
region 5 cycles FiT 11.6 11.6 11.6 11.9 11.9 12.0
10 cycles 11.5 11.6 11.7 12.1 12.0 11.9
Initial 3.2 3.2 3.3 3.3 3.3 3.3
CE-HPLC -2 weeks 40 C 3. 6 3. 8 3. 8 3. 7 - 3.
7 3. 7
4 weeks 40' C 4.3 4.3 4.3 4.3 4.2 4.3
% Pre-peaks
5 cycles FIT 3.4 3.0 3.2 3.1 3.0 3.1
10 cycles Fifi 3. 1 3. 2 2. 8 3. 1 3. 1 3. 1
Initial 96.8 96.8 96.7 96.6 96.6 96.6
CE-HPLC 2 weeks 40 C 96. 4 96. 2 96. 3 96. 3 96. 3 96. 2
% Bi Ab 4 weeks 40 C 95.6 95.7 95.6 95.7 95.8 95.8
5 cycles FiT 96.6 97.0 96.8 96.9 97.0 96.9
10 cycles F/T 96.8 96.1 97.2 96.8 96.9 96.9
Initial 0,0 0.0 0,0 0.1 0.1 0.1
CE-HPLC 2 weeks 40 C 0,0 0. 0 0, 0 0. 0 0. 0 0.0
4 weeks 40 C 0. 0 0. 0 0. 0 0. 0 0. 0 0. 0
% Post-peaks
5 cycles F/T 0.0 0.0 0.0 0.0 0.0 0.0
10 cycles F/T 0.0 0.0 0.0 0.0 0.0 0.0
CA 03016301 2018-08-30
26
As is clear from Table 9, comparing the samples containing ACE910 at 20 mg/mL
to
180 mg/mL, it was shown that the samples had an equivalent, sufficient
stability after storage at
40 C and after freeze-thawing.
.. [Industrial Applicability]
Compared to conventional formulations, the antibody solution formulations of
the
present invention have a superior stability in the solution state, and show
suppressed aggregate
formation of proteins such as the antibody molecules after storage at low,
ambient, and high
temperatures, and after freeze-thawing. The antibody solution formulations of
the present
.. invention in which deterioration reactions are difficult to occur can be
used, for example, to treat
hemophilia A by subcutaneous administration.
